Vitrolife AB (0YAY) AI Stock Analysis

Company Guidance

Management said 21% growth in technologies was “very high” and that maintaining “these type of growth levels” would be “tough,” although the funnel looks good; China’s cycles are “likely to stay that way in 2027,” while most other APAC markets are growing, albeit with “lower growth than we see in Americas or lower growth than we see in Western Europe.” The Americas Latin America headwind is expected to continue until “probably end of Q1,” with declines “slowing” and the trend “flattening out,” while Western Europe consumables growth was “high single digits.” The restructuring program remains “on plan and on time,” targeting annual savings of SEK 65 million, with an 8% gross headcount reduction, a 2.5% headcount addition in sales and marketing, IT and other roles, and a 5.5% net headcount reduction; management said there were “no major changes in headcount additions, but still some more to do.” 2027 is “set to be our best ever year” for the number and size of product launches, although revenue takes “a little bit of time” to filter through, and the time from Gate 4 to launch has been “halved from previous quarters.”